Staurosporines disrupt phosphatidylserine trafficking and mislocalize Ras proteins

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Oncogenic mutant Ras proteins are prevalent in human cancers.
• Targeting Ras is a significant challenge due to the lack of effective drugs.
• Ras membrane localization is critical for its oncogenic activity.

Purpose of the Study:

• To develop a high-content assay to identify inhibitors of Ras plasma membrane localization.
• To investigate the mechanism of action of identified inhibitors.
• To explore the therapeutic potential of these inhibitors against Ras-driven cancers.

Main Methods:

• Development of a high-content assay to screen for inhibitors of Ras plasma membrane localization.
• Treatment of cancer cells with staurosporine and analogs.
• Analysis of Ras localization, phosphatidylserine trafficking, and downstream signaling.
• Assessment of K-Ras and H-Ras specific effects.
• Evaluation of K-Ras signaling and proliferation in transformed cells.

Main Results:

• Staurosporine and analogs inhibit Ras plasma membrane binding by blocking phosphatidylserine recycling.
• These compounds are more effective against K-Ras than H-Ras.
• K-Ras undergoes degradation, while H-Ras redistributes to the Golgi.
• Ras mislocalization is independent of protein kinase C inhibition or apoptosis induction.
• Staurosporines selectively inhibit K-Ras signaling and proliferation of K-Ras-transformed cells.

Conclusions:

• Staurosporines are novel inhibitors of phosphatidylserine trafficking.
• These findings provide new insights into the role of phosphatidylserine in Ras membrane targeting.
• Staurosporines represent a validated new therapeutic target for anti-Ras drug development.